547 related articles for article (PubMed ID: 21317394)
1. NK cell adoptive transfer combined with Ontak-mediated regulatory T cell elimination induces effective adaptive antitumor immune responses.
Salagianni M; Lekka E; Moustaki A; Iliopoulou EG; Baxevanis CN; Papamichail M; Perez SA
J Immunol; 2011 Mar; 186(6):3327-35. PubMed ID: 21317394
[TBL] [Abstract][Full Text] [Related]
2. IL-4-transduced tumor cell vaccine induces immunoregulatory type 2 CD8 T lymphocytes that cure lung metastases upon adoptive transfer.
Rodolfo M; Zilocchi C; Accornero P; Cappetti B; Arioli I; Colombo MP
J Immunol; 1999 Aug; 163(4):1923-8. PubMed ID: 10438927
[TBL] [Abstract][Full Text] [Related]
3. NK cells are the crucial antitumor mediators when STAT3-mediated immunosuppression is blocked in hepatocellular carcinoma.
Sui Q; Zhang J; Sun X; Zhang C; Han Q; Tian Z
J Immunol; 2014 Aug; 193(4):2016-23. PubMed ID: 25015826
[TBL] [Abstract][Full Text] [Related]
4. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation.
Hokland M; Kjaergaard J; Kuppen PJ; Nannmark U; Agger R; Hokland P; Basse P
In Vivo; 1999; 13(3):199-204. PubMed ID: 10459491
[TBL] [Abstract][Full Text] [Related]
5. Induction of persistent tumor-protective immunity in mice cured of established colon carcinoma metastases.
Xiang R; Lode HN; Dreier T; Gillies SD; Reisfeld RA
Cancer Res; 1998 Sep; 58(17):3918-25. PubMed ID: 9731503
[TBL] [Abstract][Full Text] [Related]
6. KLRG1+ NK cells protect T-bet-deficient mice from pulmonary metastatic colorectal carcinoma.
Malaisé M; Rovira J; Renner P; Eggenhofer E; Sabet-Baktach M; Lantow M; Lang SA; Koehl GE; Farkas SA; Loss M; Agha A; Campistol JM; Schlitt HJ; Geissler EK; Kroemer A
J Immunol; 2014 Feb; 192(4):1954-61. PubMed ID: 24415778
[TBL] [Abstract][Full Text] [Related]
7. Upfront denileukin diftitox as in vivo regulatory T-cell depletion in order to enhance vaccination effects in a canine allogeneic hematopoietic stem cell transplantation model.
Knueppel A; Lange S; Altmann S; Sekora A; Knuebel G; Vogel H; Lindner I; Freund M; Junghanss C
Vet Immunol Immunopathol; 2012 Jan; 145(1-2):233-40. PubMed ID: 22173275
[TBL] [Abstract][Full Text] [Related]
8. Rapid generation of potent and tumor-specific cytotoxic T lymphocytes by interleukin 18 using dendritic cells and natural killer cells.
Tanaka F; Hashimoto W; Okamura H; Robbins PD; Lotze MT; Tahara H
Cancer Res; 2000 Sep; 60(17):4838-44. PubMed ID: 10987295
[TBL] [Abstract][Full Text] [Related]
9. Augmentation of natural killer activity, induction of IFN and development tumor immunity during the successful treatment of established murine renal cancer using flavone acetic acid and IL-2.
Hornung RL; Back TC; Zaharko DS; Urba WJ; Longo DL; Wiltrout RH
J Immunol; 1988 Nov; 141(10):3671-9. PubMed ID: 2460546
[TBL] [Abstract][Full Text] [Related]
10. Natural killer cells prevent CD28-mediated Foxp3 transcription in CD4+CD25- T lymphocytes.
Brillard E; Pallandre JR; Chalmers D; Ryffel B; Radlovic A; Seilles E; Rohrlich PS; Pivot X; Tiberghien P; Saas P; Borg C
Exp Hematol; 2007 Mar; 35(3):416-25. PubMed ID: 17309822
[TBL] [Abstract][Full Text] [Related]
11. Combination chemotherapy and IL-15 administration induce permanent tumor regression in a mouse lung tumor model: NK and T cell-mediated effects antagonized by B cells.
Chapoval AI; Fuller JA; Kremlev SG; Kamdar SJ; Evans R
J Immunol; 1998 Dec; 161(12):6977-84. PubMed ID: 9862733
[TBL] [Abstract][Full Text] [Related]
12. An IL-12/Shh-C domain fusion protein-based IL-12 autocrine loop for sustained natural killer cell activation.
Zhu L; Zhao Z; Wei Y; Marcotte W; Wagner TE; Yu X
Int J Oncol; 2012 Aug; 41(2):661-9. PubMed ID: 22581115
[TBL] [Abstract][Full Text] [Related]
13. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells.
Mulé JJ; Yang J; Shu S; Rosenberg SA
J Immunol; 1986 May; 136(10):3899-909. PubMed ID: 2871106
[TBL] [Abstract][Full Text] [Related]
14. Elimination of established murine colon carcinoma metastases by antibody-interleukin 2 fusion protein therapy.
Xiang R; Lode HN; Dolman CS; Dreier T; Varki NM; Qian X; Lo KM; Lan Y; Super M; Gillies SD; Reisfeld RA
Cancer Res; 1997 Nov; 57(21):4948-55. PubMed ID: 9354462
[TBL] [Abstract][Full Text] [Related]
15. CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner.
Ghiringhelli F; Ménard C; Terme M; Flament C; Taieb J; Chaput N; Puig PE; Novault S; Escudier B; Vivier E; Lecesne A; Robert C; Blay JY; Bernard J; Caillat-Zucman S; Freitas A; Tursz T; Wagner-Ballon O; Capron C; Vainchencker W; Martin F; Zitvogel L
J Exp Med; 2005 Oct; 202(8):1075-85. PubMed ID: 16230475
[TBL] [Abstract][Full Text] [Related]
16. Inactivated Sendai virus particles eradicate tumors by inducing immune responses through blocking regulatory T cells.
Kurooka M; Kaneda Y
Cancer Res; 2007 Jan; 67(1):227-36. PubMed ID: 17210703
[TBL] [Abstract][Full Text] [Related]
17. IL-15 promotes regulatory T cell function and protects against diabetes development in NK-depleted NOD mice.
Xia J; Liu W; Hu B; Tian Z; Yang Y
Clin Immunol; 2010 Feb; 134(2):130-9. PubMed ID: 19875339
[TBL] [Abstract][Full Text] [Related]
18. Depletion of CD4+CD25+ regulatory T cells enhances interleukin-2-induced antitumor immunity in a mouse model of colon adenocarcinoma.
Imai H; Saio M; Nonaka K; Suwa T; Umemura N; Ouyang GF; Nakagawa J; Tomita H; Osada S; Sugiyama Y; Adachi Y; Takami T
Cancer Sci; 2007 Mar; 98(3):416-23. PubMed ID: 17270031
[TBL] [Abstract][Full Text] [Related]
19. Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein.
Bachanova V; Cooley S; Defor TE; Verneris MR; Zhang B; McKenna DH; Curtsinger J; Panoskaltsis-Mortari A; Lewis D; Hippen K; McGlave P; Weisdorf DJ; Blazar BR; Miller JS
Blood; 2014 Jun; 123(25):3855-63. PubMed ID: 24719405
[TBL] [Abstract][Full Text] [Related]
20. Recombinant human prolactin improves antitumor effects of murine natural killer cells in vitro and in vivo.
Sun R; Wei H; Zhang J; Li A; Zhang W; Tian Z
Neuroimmunomodulation; 2002-2003; 10(3):169-76. PubMed ID: 12481157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
